Merck-Moderna Cancer Vaccine Targets Tumors with Experimental mRNA Tech

Merck and Moderna are collaborating on a cancer vaccine that targets tumors. The companies have been working together for several years to develop this vaccine, which is still in its experimental stages.

The vaccine uses mRNA technology to stimulate the immune system to attack cancer cells. This approach has shown promise in early trials, but more research is needed before it can be approved for use in humans.

Merck and Moderna have not released any information on when or if this vaccine will become available. The companies are continuing to conduct clinical trials to test its safety and effectiveness.